secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2023-03-13T23:59:59+00:00
Accession:  0001819790-23-000004
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus reports FY2022 net loss of $62.1M; PDUFA for TP-03 on Aug 25, 2023
-------------------------------------------------------------------------

- Full-year net loss $62.1M vs $13.8M in 2021; revenue from TP-03 out-license was $25.8M.
- Cash, cash equivalents and marketable securities $217.0M; runway into at least 2H 2026.
- TP-03 NDA accepted; PDUFA target action date August 25, 2023 for Demodex blepharitis.
- Completed enrollment of Ersa Phase 2a (MGD); topline data expected H2 2023.
- Initiated Galatea Phase 2a trial of TP-04 for rosacea; Phase 1 safety supported progression.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979023000004/0001819790-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979023000004/tars-20230313.htm
  HTML page:      https://secwatch.observer/filing/0001819790-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer